SHL Telemedicine announces results from TELE-ACS Trial

SHL Telemedicine announced the full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL’s SmartHeart 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI patients at home. A 76% reduction in the likelihood of hospital readmission within six months for patients using telemedicine. A 41% decrease in the likelihood of attending the emergency department compared to standard care recipients. Significant reductions in unplanned coronary revascularizations. Notable decreases in patient-reported symptoms, including chest pain, breathlessness, and dizziness. The TELE-ACS clinical trial, conducted at a large tertiary center in London, UK, from January 2022 to April 2023, involved 337 participants. It has set a new benchmark in the use of telemedicine for the management of post-ACS patients by reducing hospital readmissions, ED visits, lowering unplanned revascularization rates and improving patient outcomes. The investigator-initiated trial results, led by Ramzi Khamis and Nasser S. Alshahrani, were presented at the American College of Cardiology’s 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions in Atlanta. Moreover, the study was also published in the leading Journal of the American College of Cardiology.